Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with alzheimer disease

American Journal of Geriatric Psychiatry

Volumn 10, Issue 1, 2002, Pages 24-35

  Shoghi Jadid, Kooresh ^a,b,c   Small, Gary W ^a,b,c   Agdeppa, Eric D ^a,b,c   Kepe, Vladimir ^a,b,c   Ercoli, Linda M ^a,b,c   Siddarth, Prabha ^a,b,c   Read, Stephen ^a,b,c   Satyamurthy, Nagichettiar ^a,b,c   Petric, Andrej ^a,b,c   Huang, Sung Cheng ^a,b,c   Barrio, Jorge R ^a,b,c  

^a Laboratory of Structural Biology and Molecular Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 [6 [(2 FLUOROETHYL)(METHYL)AMINO] 2 NAPHTHYL]ETHYLIDENE]MALONONITRILE F 18; AMYLOID BETA PROTEIN; FLUORINE 18; MALONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; MEMORY; NEUROFIBRILLARY TANGLE; NON INVASIVE MEASUREMENT; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; PROTEIN LOCALIZATION; SENILE PLAQUE;

EID: 84903202261     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-200201000-00004     Document Type: Article

References (45)

1. Frequency of stages of Alzheimer-related lesions in different age categories
2. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease
3. Neurofibrillary pathology of Alzheimer's disease and other tauopathies
4. Potentially amyloidogenic carboxyl-terminal derivatives of the amyloid protein precursor
5. Beta-amyloid precursor protein cleavage by a membrane-bound protease
6. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives
7. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
8. The amyloid precursor protein of Alzheimer's disease and the Aβ peptide
9. Neuropathological staging of Alzheimer-related changes
10. Neocortical Lewy-body counts correlate with dementia in the Lewy-body variant of Alzheimer's disease
11. Criteria for Alzheimer's disease and the nosology of dementia with Lewy bodies
12. Staging of Alzheimer-type pathology: An interrater-intrarater study
13. Neuropathology of Alzheimer's disease: What is new since A. Alzheimer?
14. Cerebral glucose metabolic patterns in Alzheimer's disease: Effect of gender and age at dementia onset
15. Regional cerebral glucose metabolism and postmortem pathology is Alzheimer's disease
16. Mapping histology to metabolism: Coregistration of stained whole-brain sections to premortem PET in Alzheimer's disease
17. Binding characteristics of radiofluorinated 6-dialkylamino-2-napthylethylidine derivatives as PET imaging probes beta-amyloid plaques in Alzheimer's disease
18. In vivo and in vitro labeling of plaques and tangles in the brain of an Alzheimer's disease patient: A case study
19. In vitro binding characteristics of FDDNP and a new analog for synthetic beta-amyloid fibrils
20. PET imaging of tangles and plaques in Alzheimer disease with a highly hydrophobic probe
21. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease
22. Mini-mental State: A practical method for grading the cognitive state of patients for the clinician
23. Le test de copie d'une figure complexe
24. A general technique for interstudy registration of multifunction and multimodality images
25. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease
26. Distribution of cerebral degeneration in Alzheimer's disease: A clinico-pathological study
27. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects
28. Development of a monoclonal antibody specific for beta/A4 amyloid in Alzheimer's disease brain for application to in-vivo imaging of amyloid angiopathy
29. Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease
30. Chrysamine-G binding to Alzheimer and control brain: Autopsy study of a new amyloid probe
31. Technetium complexes for the quantitation of barin amyloid
32. Preparation of Tc-99m-N2S2 conjugates of chrysamine G, potential probes for the beta-amyloid protein of Alzheimer's disease
33. Vector-mediated delivery of 1251-labeled beta-amyloid peptide A beta 1-40 through the bloodbrain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex
34. Receptor assays, in vitro and in vivo
35. Relationship between plaques, tangles, and dystrophic processes in Alzheimer's disease
36. Alzheimer neurofibrillary lesions: Molecular nature and potential roles of different components
37. Solvent effects on self-assembly of beta-amyloid peptide
38. Neuroreceptor assay with positron emission tomography: Equilibrium vs. Dynamic approaches
39. Striatal kinetic modeling of FDOPA with a cerebellar-derived constraint on the distribution of volume of 3OMFD: A PET investigation using nonhuman primates